Recommendations of International Society of Amyloidosis on the Management of Patients with Systemic Amyloidosis During the COVID-19 Pandemic | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Guides & Guidelines

Recommendations of International Society of Amyloidosis on the Management of Patients with Systemic Amyloidosis During the COVID-19 Pandemic

key information

source: International Society of Amyloidosis

year: 2020

summary/abstract:

Patients with systemic amyloidosis should be considered at increased risk of complications and mortality in case of SARS-CoV2 infection. This may be particularly relevant for patients with heart involvement, because subjects with SARS-CoV2 infection and pre-existing cardiovascular disease have an increased risk of severe clinical manifestations and death. The infection has been associated with cardiovascular complications, and therapies under investigation for COVID-19 may have cardiovascular side effects.

In particular, COVID-19 treatment commonly includes hydroxychloroquine and azithromycin. This combination is associated with the risk of ventricular arrhythmias related to QT prolongation, and if started, close cardiological monitoring or at least regular ECG with QTc is required. This is particularly relevant in patients with amyloid cardiac involvement. In addition, patients with renal involvement might be more susceptible to COVID-19, since they have impaired humoral immunity.

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2025 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close